약물유전체학 시장 : 제품별, 기술별, 용도별, 최종사용자별 - 세계 예측(-2031년)

The pharmacogenomics market is expected to reach $19.5 billion by 2030, at a CAGR of 8.9% from 2024 to 2031.

With extensive primary and secondary research and in-depth analysis of the market scenario, the report studies the key industry drivers, restraints, challenges, and opportunities. The growth of the pharmacogenomics market is attributed to the growing therapeutic applications of pharmacogenomic biomarkers, the increasing adoption of personalized medicines, the rising geriatric population and chronic disease prevalence, and the U.S. FDA's and EMA's recommendations for using pharmacogenomic data in drug discovery & development. However, the high costs of personalized medicines restrain the growth of this market.

Furthermore, the increasing application of pharmacogenomics in the treatment of neurological disorders and cancers, the development of new, more advanced diagnostic tools with improved accuracy, and growing awareness regarding adverse drug reactions are expected to generate growth opportunities for the players operating in the pharmacogenomics market. However, low awareness about pharmacogenomics and personalized medicine, the limited understanding of genetic testing and its benefits, and the lack of reimbursements for genetic testing and precision medicine are major challenges impacting market growth.

Based on offering, the global pharmacogenomics market is segmented into consumables, instruments, and software & services. In 2024, the consumables segment is expected to account for the largest share of the market. The largest market share of this segment is attributed to the recurrent use of consumables over instruments and the high burden of chronic diseases. Moreover, the high increasing prevalence of chronic diseases coupled with the focus of players for the launch of advanced and better reagents & kits drives the segment growth.

Based on technology, the global pharmacogenomics market is segmented into polymerase chain reaction (PCR), sequencing, microarray, mass spectrometry, electrophoresis, and other technologies. In 2024, the polymerase chain reaction (PCR) segment is expected to account for the largest share of the pharmacogenomics market. The large market share of this segment is attributed to the high sensitivity, accuracy, low sample volume requirements, and cost-effectiveness coupled with the high presence of PCR base across all the end users, initiatives by players to launch and get approvals for new PCR products for pharmacogenomics, and a wide range of applications of the PCR.

Based on application, the global pharmacogenomics market is segmented into oncology, mental health cardiology, neurological disorders, infectious diseases, and other applications. The oncology segment is expected to register the fastest CAGR during the forecast period of 2024-2031. The fast growth of this segment is attributed to the increasing prevalence of cancer cases and the need for targeted cancer treatment, growing demand for precision oncology, and growing research activities for precision oncology.

Based on end user, the global pharmacogenomics market is segmented into hospitals & diagnostic laboratories, academic and research institutes, and other end users. In 2024, the hospitals & diagnostic laboratories segment is expected to account for the largest share of the global pharmacogenomics Market. The large market share of this segment is attributed to the growing adoption of precision medicine, the growing prevalence of chronic diseases, the large number of clinical trials conducted at hospitals and diagnostic laboratories, and the focus of pharmacogenomic testing services companies on acquisitions and launches of pharmacogenomic testing services. For instance, in 2023, Incite Health Pty Limited (Australia), a pharmacogenomic testing company, acquired CNSDose LLC (U.S.), a pharmacogenomic test provider.

An in-depth analysis of the geographical scenario of the pharmacogenomics market provides detailed qualitative and quantitative insights into five major geographies: North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa, along with the coverage of major countries in each region. Asia-Pacific is slated to register the highest CAGR during the forecast period. Rising government spending to increase testing capacities; increasing cases of inherited diseases such as Down Syndrome, cystic fibrosis, sickle cell disease, colon (colorectal) cancer, and breast cancer; growing awareness about the significance of genetic tests; and increasing government initiatives promoting genetic testing contribute to the growth of the market.

Some of the key players operating in the global pharmacogenomics market are F. Hoffmann-La Roche AG (Switzerland), Abbott Laboratories (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Illumina, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Danaher Corporation (U.S.), QIAGEN N.V. (Netherlands), and Pacific Biosciences of California, Inc. (U.S.).

Scope of the Report:

Pharmacogenomics Market, by Offering

• Instruments
• Consumables
• Software & Services

Pharmacogenomics Market, by Technology

• Polymerase Chain Reaction
• DNA Sequencing
• Electrophoresis
• Microarray
• Mass Spectrometry
• Other Technologies

(Note: Other Technologies include nucleic acid amplification technology and in situ hybridization)

Pharmacogenomics Market, by Application

• Oncology
• Mental Health
• Cardiology
• Neurological Disorders
• Infectious Diseases
• Other Applications

(Note: Other Applications include pain management, adverse drug reactions, autoimmune diseases, metabolic disorders, pulmonary diseases, hematology, dermatology, transplantation, urology, analgesia, anesthesiology, antidotal therapy, and forensic pathology)

Pharmacogenomics Market, by End User

• Hospitals & Diagnostic Laboratories
• Academic & Research Institutes
• Other End Users

(Other End Users include pharmaceutical & biotechnology companies, clinical research organizations (CROS), and forensic laboratories)

Pharmacogenomics Market, by Geography

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Rest of Europe (RoE)
• Asia-Pacific (APAC)
  • Japan
  • China
  • India
  • Rest of Asia-Pacific (RoAPAC)
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America (RoLATAM)
• Middle East & Africa

TABLE OF CONTENTS

1. Introduction

• 1.1. Market Definition & Scope
• 1.2. Market Ecosystem
• 1.3. Currency & Limitations
• 1.4. Key Stakeholders

2. Research Methodology

• 2.1. Research Approach
• 2.2. Process Of Data Collection and Validation
  • 2.2.1. Secondary Research
  • 2.2.2. Primary Research/Interviews with Key Opinion Leaders from The Industry
• 2.3. Market Sizing and Forecasting
  • 2.3.1. Market Size Estimation Approach
  • 2.3.2. Growth Forecast Approach
• 2.4. Assumptions For the Study

3. Executive Summary

4. Market Insights

• 4.1. Overview
• 4.2. Factors Affecting Market Growth
  • 4.2.1. Market Dynamics
    • 4.2.1.1. Growing Therapeutic Applications of Pharmacogenomic Biomarkers Supporting Market Growth
    • 4.2.1.2. Increasing Adoption of Personalized Medicines Driving the Demand for Pharmacogenomics
    • 4.2.1.3. Rising Geriatric Population and Chronic Disease Prevalence Boosting Pharmacogenomic Research and Testing
    • 4.2.1.4. The U.S. FDA's And EMA's Recommendations for Using Pharmacogenomic Data in Drug Discovery & Development Accelerating Market Expansion
    • 4.2.1.5. Growing Awareness Regarding Adverse Drug Reactions (ADRs) Generating Opportunities for Market Players
    • 4.2.1.6. Low Awareness About Pharmacogenomics and Personalized Medicine to Remain a Major Challenge for Market Stakeholders
    • 4.2.1.7. Lack Of Reimbursements for Genetic Testing and Precision Medicine Impacting Market Growth
  • 4.2.2. Factors Analysis
• 4.3. Key Trends
  • 4.3.1. Declining Costs of Sequencing Making Pharmacogenomic Testing More Affordable
  • 4.3.2. Increasing Potential of AI In Pharmacogenomics
• 4.4. Regulatory Analysis
  • 4.4.1. U.S
  • 4.4.2. Canada
  • 4.4.3. Europe
  • 4.4.4. China
  • 4.4.5. Japan
  • 4.4.6. India
  • 4.4.7. Latin America
  • 4.4.8. Middle East & Africa
• 4.5. Pricing Analysis
• 4.6. Porter's Five Forces Analysis
  • 4.6.1. Bargaining Power of Buyers
  • 4.6.2. Bargaining Power of Suppliers
  • 4.6.3. Threat Of Substitutes
  • 4.6.4. Threat Of New Entrants
  • 4.6.5. Degree Of Competition

5. Pharmacogenomics Market Assessment-by Offering

• 5.1. Overview
• 5.2. Consumables
• 5.3. Instruments
• 5.4. Software & Services

6. Pharmacogenomics Market Assessment-by Technology

• 6.1. Overview
• 6.2. Polymerase Chain Reaction (PCR)
• 6.3. Sequencing
• 6.4. Microarray
• 6.5. Mass Spectrometry
• 6.6. Electrophoresis
• 6.7. Other Technologies

7. Global Pharmacogenomics Market Assessment-by Application

• 7.1. Overview
• 7.2. Oncology
• 7.3. Mental Health
• 7.4. Infectious Diseases
• 7.5. Cardiology
• 7.6. Neurological Disorders
• 7.7. Other Applications

8. Pharmacogenomics Market Assessment-by End User

• 8.1. Overview
• 8.2. Hospitals & Diagnostic Laboratories
• 8.3. Academic & Research Institutes
• 8.4. Other End Users

9. Pharmacogenomics Market Assessment-by Geography

• 9.1. Overview
• 9.2. North America
  • 9.2.1. U.S.
  • 9.2.2. Canada
• 9.3. Europe
  • 9.3.1. Germany
  • 9.3.2. France
  • 9.3.3. U.K.
  • 9.3.4. Italy
  • 9.3.5. Spain
  • 9.3.6. Rest Of Europe
• 9.4. Asia-Pacific
  • 9.4.1. China
  • 9.4.2. Japan
  • 9.4.3. India
  • 9.4.4. Rest Of Asia-Pacific
• 9.5. Latin America
• 9.6. Middle East & Africa

10. Competition Analysis

• 10.1. Overview
• 10.2. Key Growth Strategies
• 10.3. Competitive Benchmarking
• 10.4. Competitive Dashboard
  • 10.4.1. Industry Leaders
  • 10.4.2. Market Differentiators
  • 10.4.3. Vanguards
  • 10.4.4. Emerging Companies
• 10.5. Market Ranking (2023)
  • 10.5.1. Thermo Fisher Scientific, Inc. (U.S.)
  • 10.5.2. Illumina, Inc. (U.S.)
  • 10.5.3. Danaher Corporation (U.S.)
  • 10.5.4. F. Hoffmann-La Roche Ltd. (Switzerland)

11. Company Profiles (Business Overview, Financial Snapshot, Product Portfolio, Strategic Developments, and SWOT Analysis)

• 11.1. F. Hoffmann La-Roche Ag
• 11.2. Thermo Fisher Scientific, Inc.
• 11.3. Illumina, Inc.
• 11.4. Danaher Corporation
• 11.5. Agilent Technologies, Inc.
• 11.6. Qiagen N.V.
• 11.7. Abbott Laboratories
• 11.8. Bio-Rad Laboratories, Inc.
• 11.9. PerkinElmer, Inc.
• 11.10. Pacific Biosciences of California, Inc.

(Note: SWOT Analysis of Top 5 Companies Will Be Provided)

12. Appendix

• 12.1. Available Customization
• 12.2. Related Reports